SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2020

Commission File Number: 001-36697

DBV TECHNOLOGIES S.A.

(Translation of registrant s name into English)

177-181 avenue Pierre Brossolette

92120 Montrouge France

(Address of principal executive office)

Indicate by check mark whether

the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,

thereunto duly authorized.

DBV Technologies Reports First Half 2020 Financial Results

DBV Technologies (Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half

2020 financial results. The interim financial report is available on the Investor Relations section of the Company s website, www.dbv-technologies.com/investor-relations/. First half 2020 financial

statements were subject to a limited review by the Company s external auditors.

In the first half of this year, we focused on working with

the FDA and submitting a robust data package to support its review of Viaskin Peanut. We also executed a restructuring to extend our runway and better position our business to prepare to

bring this important treatment to patients, said Daniel Tass , Chief Executive Officer of DBV Technologies. Recently, we published encouraging results from the PEOPLE Phase III open-label extension study of Viaskin Peanut in The

Journal of Allergy and Clinical Immunology, highlighting the robust, long term clinical benefit of Viaskin Peanut with a decrease in adverse events among children with peanut allergy. We expect to hear from the FDA on next steps with our BLA filing

imminently and look forward to providing an update at that time.

About DBV Technologies

DBV Technologies is developing Viaskin , an investigational proprietary technology platform with broad

potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT , DBV s method of delivering biologically active compounds to the immune system through

intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV s food allergies programs include ongoing

clinical trials of Viaskin Peanut (DBV712). DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company s ordinary shares are traded on

segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global

Select Market (Ticker: DBVT).

Forward Looking Statements

This press release may contain forward-looking statements and estimates, including statements regarding the potential of Viaskin Peanut as a treatment for peanut-allergic children and the Company s planned interactions with the FDA regarding Viaskin Peanut and the target action date for the Company s BLA. These

forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause

actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19

pandemic. Furthermore, the timing of any action by the FDA and possible regulatory paths forward cannot be guaranteed. A further list and description of these risks, uncertainties and other risks can be found in the Company s regulatory filings

with the French Autorit des March s Financiers, the Company s Securities and Exchange Commission filings and reports, including in the Company s Annual Report on Form 20-F for the year

ended December 31, 2019, and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking

statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained

in this Press Release.

Senior Director, Investor Relations & Strategy